In an initial trial, Bayer claims Parkinson's stem cell therapy improved symptoms

An experimental stem cell therapy created by Bayer's American subsidiary, BlueRock, showed signs of reducing the symptoms of Parkinson's disease.

The German drugmaker announced in June that the initial 12-patient trial had been successful in a brief summary, claiming it to be the first success of a stem-cell Parkinson's therapy, but withheld further information until a medical conference.

According to a statement released on Monday, the seven participants who received the high dose experienced 2.16 hours longer on average each day of symptoms that were under control and 1.91 hours less of deteriorating symptoms.

The average period of well-controlled symptoms was 0.72 hours longer per day for the five participants who were taking a lower dose, while the time of deteriorating symptoms was 0.75 hours shorter.

There were no significant safety concerns, and the treatment was well tolerated.

Christian Rommel, head of drug research and development at Bayer, characterized the successful conclusion of this Phase I clinical trial as a clear advancement.

Human pluripotent embryonic stem cells were converted into dopamine-producing nerve cells for BlueRock's experimental therapy. They were inserted into the brain to rebuild the neuronal networks that Parkinson's disease had devastated.

Additionally, medications to stop the immune system from attacking the new cells were administered.

In Copenhagen, Denmark, the findings were presented at the International Congress of Parkinson's Disease and Movement Disorders.

Progressive brain damage is a symptom of Parkinson's disease, which has no known cure and affects more than 10 million people worldwide. Loss of muscle control, tremors, and muscle rigidity are common symptoms, and some individuals also have dementia.